The AdenoPlus test is designed to detect adenovirus. Nicox said the test is a four-step process that takes less than two minutes to complete and provides a result in 10 minutes.
“With AdenoPlus, Nicox has taken a first step towards fulfilling its objective of starting a commercial business in the ophthalmic space,” said Michele Garufi, chairman and CEO of Nicox, in the release. “We have established a specialized sales team on the ground who will be marketing and selling this innovative and easy-to-use product to eyecare practitioners across the United States, bringing a new, fast and accurate diagnostic option that will aid in the differential diagnosis of acute conjunctivitis.”
Nicox is headquartered in France, and has a U.S. subsidiary in Dallas.
Related Articles on New Technology:
Boston Scientific Launches Guidewire for Crossing Resistant Lesions
PENTAX Set to Launch New Endoscopic Imaging Platform
Vidacare Launches New Accessory Tray for Bone Lesion Access and Biopsy
